An infusion drug that treats a rare disease has caught the eye of lawyers, who have filed over a dozen cases with more expected in the months ahead.
The drug, Tepezza, which the U.S. Food and Drug Administration approved in 2020, treats thyroid eye disease through intravenous infusions.